Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) and Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.
Valuation and Earnings
This table compares Milestone Pharmaceuticals and Sol-Gel Technologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Milestone Pharmaceuticals | $1.55 million | 61.27 | -$63.06 million | ($0.69) | -1.11 |
| Sol-Gel Technologies | $19.39 million | 10.29 | -$6.13 million | ($5.64) | -10.82 |
Sol-Gel Technologies has higher revenue and earnings than Milestone Pharmaceuticals. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Milestone Pharmaceuticals and Sol-Gel Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Milestone Pharmaceuticals | N/A | -288.33% | -58.27% |
| Sol-Gel Technologies | -910.14% | -44.05% | -36.96% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Milestone Pharmaceuticals and Sol-Gel Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Milestone Pharmaceuticals | 1 | 1 | 4 | 1 | 2.71 |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
Milestone Pharmaceuticals presently has a consensus target price of $6.40, suggesting a potential upside of 739.01%. Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 223.72%. Given Milestone Pharmaceuticals’ higher probable upside, equities analysts plainly believe Milestone Pharmaceuticals is more favorable than Sol-Gel Technologies.
Risk and Volatility
Milestone Pharmaceuticals has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
Summary
Sol-Gel Technologies beats Milestone Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
About Sol-Gel Technologies
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
